SCHEMBL7013196

SCHEMBL7013196

CCC(CO)Nc1nc(NCc2ccccc2)c2[nH]c(Cl)nc2n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 12/20 0.60
CDK2 P24941 10/20 0.57
CDK5 Q00535 9/20 0.57
CDK7 P50613 6/20 0.57
CDK9 P50750 6/20 0.57
CCNE1 P24864 5/20 0.57
CDK5R1 Q15078 5/20 0.57
CCNT1 O60563 4/20 0.57
CCNH P51946 4/20 0.57
CCNA2 P20248 6/20 0.56
CCNA1 P78396 5/20 0.56
CSNK1D P48730 2/20 0.56
CLK2 P49760 2/20 0.56
CSNK1G2 P78368 2/20 0.56
DYRK1A Q13627 2/20 0.56
CLK4 Q9HAZ1 2/20 0.56
CSNK1G1 Q9HCP0 2/20 0.56
CACNA1B Q00975 2/20 0.56
CCNK O75909 2/20 0.56
CCNE2 O96020 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3444040 0.82 CDK2 (0.61) CDK1CDK2CDK5CDK7CDK9
SCHEMBL2913189 0.76 CDK2 (0.70) CDK1CDK2CDK5CDK7CDK9
SCHEMBL7011141 0.76 APP (0.55) CDK1CDK2CYP1A2CYP2D6TSHR
SCHEMBL24669720 0.74 CDK2 (0.65) CDK1CDK2CDK5CDK7CDK9
SCHEMBL3444036 0.74 CDK2 (0.68) CDK1CDK2CDK5CDK7CDK9
SCHEMBL5057443 0.74 CDK1 (0.64) CDK1CDK2CDK5CDK7CDK9
SCHEMBL3444129 0.73 CDK2 (0.65) CDK1CDK2CDK5CDK7CDK9
SCHEMBL7013199 0.73 CDK1 (0.39) CDK1CDK2CDK5CCNE1CCNE2
SCHEMBL2913185 0.73 CDK2 (1.00) CDK1CDK2CDK5CDK7CDK9
SCHEMBL2913193 0.73 CDK2 (1.00) CDK1CDK2CDK5CDK7CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030191086-A1 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof USTAV EXPERIMENTALNI BOTANIKY AV CR 2003-10-09 US disclosed
EP-1147108-B1 SUBSTITUTED NITROGEN HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL USE THEREOF USTAV EX BOTAN AKADEMIE VED CE (CZ) 2003-08-13 EP disclosed
US-6552192-B1 Inhibiting cyclin dependent kinase proteins, viruses, and immunostimulation; antimitotic, antiviral, anticancinogenic, antidegenerative, immunosuppressive USTAU EXPERIMENTALNI BOTANIKY AV-CR (CZ) 2003-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191086-A1 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof CDK4, CDK5, CCNI CDK1 6/4885CDK2 11/4885CDK5 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.